BIOGEN INC.

(BIIB)

CIK 875045 · SEC filings only

Not yet gradedGuidance record
harness minimum not met

company entity

1 resolved promise

Sector median (Life Sciences): B across 7 graded companies

Not enough comparable guidance to grade

1 of the 4 resolved guidance promises needed to publish a reliability grade. Some of this company’s guidance has no reported figure we can compare it with. It is shown below, never scored; the line under each statement says why. Here's what we're tracking — we never show a grade we can't back with receipts.

Resolved promises

Pro

Full say-do history

Free scorecards show the 12 most recent resolved guidance promises. See the complete multi-year record with Pro.

See Pro →

Guidance by basis

1 of 2 guidance figures that were graded or dropped for basis could not be graded on the same basis (50%). Guidance marked “not judged” is in neither number.

Guidance type	Said	Graded	Dropped	Other
Revenue · basis not stated	2	0	0	2
EPS · GAAP	2	1	0	1
EPS · non-GAAPcannot be graded	2	0	1	1

Said counts every revenue and EPS guidance figure on record. Dropped counts figures whose period was reported but which have no comparable GAAP actual in SEC XBRL. Other covers open, superseded, withdrawn and otherwise unresolved figures. The coverage note below counts every figure shown but not graded, including figures whose period has not been reported, so it can be larger.

How the site-wide rate is measured

Compare across companies

Guidance shown, not graded (2)

We show what was said — with its source filing — but never score it. The line under each statement says why.

eps guidance fy · Oct 25, 2012
Non-GAAP diluted EPS is expected to be between $6.40 and $6.50.
Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
eps guidance fy · May 1, 2012
Non-GAAP diluted EPS is expected to be above $6.15.
Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗

Open promises (1) · 2 superseded

Open · revenue guidance fy

Revenue growth is expected to be in the mid to high-single digits versus 2011.

unresolved — no outcome on filereceipt

Superseded · eps guidance fy

GAAP diluted EPS is expected to be above $5.54.

revised by a later guidancereceipt

Superseded · revenue guidance fy

Revenue growth is expected to be in the mid-single digits versus 2011.

revised by a later guidancereceipt

Credibility timeline

20132013

Timeline as a list

Feb 5, 2013ABOVEGAAP diluted EPS is expected to be between $5.63 and $5.73.